In a nutshell
The aim of this study was to compare the heath related quality of life (HRQOL) of patients treated with enzalutamide (Xtandi) or bicalutamide (Casodex). It was concluded that enzalutamide led to a better HRQOL in patients with metastatic castration resistant prostate cancer when compared to bicalutamide.
Some background
Androgen deprivation therapy (ADT) is a type of hormone therapy for prostate cancer. ADT reduces the level of male sex hormones, such as testosterone, involved in cancer growth. Another type of therapy to lower androgen levels in surgical castration (removal of the testicles). Over time, however, cancer can continue to spread despite standard hormone therapy. This is known as metastatic castration-resistant prostate cancer (mCRPC).
Both enzalutamide and bicalutamide are antiandrogen therapies often used in mCRPC. It is unknown which of these allows the patient to have a better HRQOL.
Methods & findings
375 men with mCRPC took part in this study. They had little or no symptoms of mCRPC. 49% were treated with 160 mg a day of enzalutamide. 51% were treated 50 mg a day of bicalutamide. HRQOL was measured by questionnaires.
Men treated with enzalutamide had a 26%-36% (depending on the questionnaire) lower risk of their HRQOL becoming worse compared to those who were treated with bicalutamide.
The bottom line
This study concluded that enzalutamide led to a higher HRQOL when compared to bicalutamide in men with CRPC.
The fine print
A small number of patients were involved. A larger study would provide more reliable results.
What’s next?
Speak to your physician about enzalutamide as a possible treatment option.
Published By :
European Urology
Date :
Aug 03, 2016
